[Click eStock] "Samsung Bio, 4th Plant Sales Begin in Earnest... Target Price Raised to 1.2 Million Won"

Daishin Securities raised the target price of Samsung Biologics to 1.2 million KRW on the 4th. It is expected that earnings will improve as sales from the 4th plant are fully recognized.

Lee Hee-young, an analyst at Daishin Securities, stated, "Sales from the 4th plant began to be fully recognized starting from the third quarter of this year," adding, "The timing for recognizing sales from the 5th to 8th plants, which are scheduled to operate in the future, was advanced from 1 year and 6 months to 1 year, leading to an upward revision of sales estimates."

The analyst explained, "Recently, the global demand for antibody drugs has surged, resulting in large-scale orders for Samsung Biologics," and added, "In the mid to long term, benefits from the U.S. Biosecurity Act are also expected."

He evaluated, "The subsidiary Bioepis is also improving its performance thanks to the expansion of biosimilar sales and a high exchange rate (depreciation of the Korean won)," and noted, "Preparations for new product launches are progressing smoothly."

This content was produced with the assistance of AI translation services.